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Abstract
TNF inhibitors are biologic DMARDs approved for the treatment of active RA in mid-1990s. They still
represent a valuable therapeutic option to control the activity, disability and radiographic progression of
the disease. In the context of TNF inhibitors, there are currently several molecules and different admin-
istration routes that provide optimal treatment personalization, allowing us to respond to a patient’s needs
in the best possible way. The increasing use of TNF inhibitors has not only improved the management of
RA, but it has also helped in our understanding of the pathogenetic mechanisms of the disease. This
review focuses on the basis of this targeted therapy and on the knowledge gained from their use about
therapeutic effects and adverse events. Effectiveness analysed from drug registries and safety issues are
presented together with recent data on infections (in particular, Mycobacterium tuberculosis and hepatitis
B), cancer (lymphoma, skin cancers) and cardiovascular risk.
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Rheumatology key messages
. Biologics have revolutionized the way we treat RA.
. TNF inhibitors were the first biologics used both in randomized controlled trials and in clinical practice.
. TNF inhibitors are effective and safe and represent a valid option for RA.
Introduction
The last 20 years have seen a revolution in the therapeutic
approach to RA. The aim of therapy has gone from the
control of symptoms to the treat-to-target strategy based
on a combined approach focusing not only on symptom
control, but also on prevention of structural damage, nor-
malization of function and social participation [1]. Part of
this revolution is due to improvement in the use of con-
ventional synthetic DMARDs (csDMARDs) as soon as the
diagnosis is made but also the efficacy that targeted
therapies have demonstrated in randomized clinical trials
(RCTs) and registries.
Neutralizing the effect of TNF in RA has been the first
targeted approach and one of the most successful so far.
This short review summarizes the role played by TNF in
RA and what the use of TNF inhibitors (TNFis) has taught
us about the articular and extra-articular manifestations of
a complex and systemic disease such as RA.
The TNF-dependent cytokine cascade
The inflammatory milieu in the synovial compartment
in RA is regulated by a complex network of cytokines
and chemokines, leading to induction and maintenance
of the inflammatory response by activating endothe-
lial cells and attracting immune cells to the synovial com-
partment. Activated fibroblasts, together with activated
T and B cells, monocytes and macrophages, ultimately
trigger osteoclast generation that leads to bone erosion
[24].
This knowledge led some groups in the late 1980s
and early 1990s to use pro-inflammatory cytokines as a
therapeutic target. Brennan et al. [5] performed a pivotal
experiment in 1989, blocking cytokines produced in cul-
tures of rheumatoid synovium using antibodies [6] demon-
strating that the blockade of TNF-a downregulated most
of the other pro-inflammatory cytokines. This assumption
was confirmed in animal models and also in vitro and
in vivo, using patients’ serum samples and blood [7].
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TNF represents an important host defence molecule
and the first cytokine appearing after injuries. Other pro-
inflammatory mediators are produced much later and
mostly depend on the prior release of TNF [8]. TNF-a
blockade has been shown to have clinical benefits: a re-
duction in cytokine blood levels and their decreased
access to the brain can explain a lower level of fatigue
and mood improvement, a decrease in local TNF levels
normalizes the pain threshold and probably the most rele-
vant factor is connected with the reduction of leucocyte
trafficking to the joints, mediated by a reduction in both
chemokine expression and adhesion molecules [9].
Among the TNFis, five drugs have been approved, one
for i.v. use (infliximab) and four for s.c. administration
(adalimumab, certolizumab pegol, etanercept and golimu-
mab). Etanercept is a recombinant human TNF dimeric
receptor fusion protein, while the others are mAbs or frag-
ments of mAbs. The main features of TNFis currently
available for RA treatment are shown in Table 1.
Biosimilars of infliximab and etanercept have also been
available since 2013 and 2016, respectively.
TNFis: what did RCTs teach us?
The first formal randomized phase II double-blind trial with
TNFi was conducted in 1994. Results of a single infusion
of infliximab, compared with placebo, provided the first
favourable evidence that a specific cytokine blockade
can be effective in active RA [10] and this was later cor-
roborated by repeated dosing trials [11, 12]. A larger multi-
centre double-blind trial confirmed that infliximab was
significantly better than placebo in all measures of disease
activity and the clinical response was greater in infliximab
groups compared with MTX alone [13]. In the same years
similar data were also published for etanercept [1416].
The main limitation of these first trials is related to the type
of patients enrolled: first experiences with TNFis refer to a
population with a long-standing severe joint disease.
Years later, the availability of Early Arthritis Clinics, the
attention paid to an early diagnosis of RA, knowledge of
the treat-to-target strategy and the chance to use more
effective treatments allowed us to carry out trials with
TNFis in patients who presented the disease at an early
stage.
Today, clinical, functional and structural results represent
the main outcomes in the management of RA. The simultan-
eous achievement of these three outcomes, defined as com-
prehensive disease control [17], has been shown to be
associated with significant improvement in a patient’s work-
related outcome, quality of life, pain and fatigue, but also with
a reduction of health carerelated costs and a decreased
mortality rate. This is the main reason why current recom-
mendations state that the treatment of RA should focus on
achieving clinical remission to inhibit disease progression and
improve physical function, or at least reach low disease ac-
tivity [1, 18], which is reflected quite well by the achievement
of a 70% improvement in ACR criteria. However, such a
stringent response is difficult to obtain in patients with estab-
lished disease, even during clinical trials [19].
Indeed, there is considerable evidence that treating arthritis
early is much better than treating it late [20]. In the OPTIMA
trial, patients with very short disease duration, treated with
MTX with incomplete disease control, received an additional
TNFi (adalimumab), showing a much greater response than in
previous trials that used long-standing disease populations
[21]. In general, all biologic DMARDs (bDMARDs) showed
enhanced efficacy when combined with MTX in particular
and, among other csDMARDs, with leflunomide [2225].
Current recommendations state that addition of a bDMARD
should be considered when the treatment target has not
been achieved with the first csDMARD strategy. This ap-
proach is particularly necessary when poor prognostic fac-
tors are present [18]. The use of TNFi is strongly supported
by the availability of long-term registry data concerning their
use, as we will discuss later. The progression of structural
damage is strongly inhibited by a biologic monotherapy
rather than by MTX monotherapy, despite not being as ef-
fective as combined treatment. The combination of a biologic
with MTX has shown clinical and functional superiority com-
pared with monotherapy with a biologic or with MTX alone
[26, 27]; nevertheless, a substantial number of patients do not
tolerate csDMARDs [28]. A recent meta-analysis showed that
etanercept monotherapy is as effective as monotherapy with
anti-IL-6 (tocilizumab) [29].
Clinical and structural efficacy is similar across all types
of bDMARDs: when a patient does not achieve the treat-
ment target with a bDMARD (plus MTX), any other
TABLE 1 Currently available TNFis for RA
TNF inhibitor Molecule type
Year of
release
Half-life,
days
Route of
administration
Monotherapy
approval
Adalimumab (ADA) Human mAb IgG1 2003 14 Subcutaneous Yes
Certolizumab pegol (CZP) Humanized Fab frag-
ment conjugated to a
polyethylene glycol
2009 14 Subcutaneous Yes
Etanercept (ETN) Fusion protein of TNF
receptor 2 and IgG1
Fc component
2000 46 Subcutaneous Yes
Golimumab (GLM) Human mAb IgG1 2009 14 Subcutaneous No
Infliximab (IFX) Chimeric mAb IgG1 1999 810 Intravenous No
Fab: fragment antigen binding.
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bDMARD can be used [18]. Moreover, the sequential use
of TNFis after an initial lack of response seems to provide
similar outcomes to biologics with different mechanisms
of action, at least in clinical trials [3032].
The appearance of antidrug antibodies is another pivotal
aspect regarding efficacy and treatment persistence, in par-
ticular related to a secondary non-response to bDMARDs.
Currently no evidence has been provided to support routine
testing for antidrug antibodies and it has been shown that
combination therapy with a low dose of MTX can reduce the
incidence of immunogenicity, which explains the better
result obtained using a combination therapy [12, 33].
TNFis in real life: data from registries
Registries are a precious tool to monitor and survey commer-
cial drugs in the long run. Their follow-up allows us to identify
side effects and serious events not previously observed in
RCTs. In the past decade, several registries of patients with
RA have been established, as presented in Table 2 [34].
Effectiveness
TNFis have been demonstrated to be effective and well
tolerated in a great proportion of patients from RCTs [37],
but in clinical practice, primary and secondary failures of
TNFi strategies have been shown to affect between a third
and half of treated subjects, in particular patients with long-
standing disease [38, 39]. A poorer EULAR clinical response
has been shown to be associated with the number of
DMARDs previously used. Non-response is strongly pre-
dicted by a high level of disability and a daily corticosteroid
dose >5 mg/day, whereas a good response is associated
with the concomitant use of MTX, male gender and higher
28-joint DAS (DAS28) scores at baseline [40].
Moreover, TNFi therapy is effective in both high and mod-
erate disease activity [41], with higher rates of remission in
the latter. Predictive factors in patients with high disease ac-
tivity were pointed out by the analysis of the Italian Lombardy
Rheumatology Network (LORHEN) registry, showing that
lower age at the first TNFi and the absence of comorbidities
independently predict the EULAR response, while male
gender is a positive response predictor for both groups
[42]. These findings could be explained by the potential
effects of TNFis on the neuroendocrine axis, which include
higher levels of anti-inflammatory androgens in the synovial
tissue of males compared with females [43]. The effective-
ness of a TNFi therapy in reducing RA-related disability has
also been confirmed in patients with highly active and long-
standing RA: patients can achieve a good functional recovery
even after years. Starting TNFi therapy not only reduced dis-
ability from moderate to mild, but patients who achieved clin-
ical remission during the follow-up are recovering from
disability, regardless of disease duration [44].
Patients who suboptimally respond to a TNFi or fail to
maintain an initially good response over time may benefit
from switching to a second TNFi after failure of the first
one, although their probability to achieve a EULAR
response is slightly lower than that observed in patients
who start TNFi treatment [45, 46].
TNFis have different molecular structures, sites of action
and dosing regimens, so for these reasons, switching to a
second TNFi has become common clinical practice. Results
from the British Society for Rheumatology Biologics
Register-RA showed that 73% of patients switching to a
second TNFi were still on treatment after a mean of
15 months of follow-up [47], and data from the Spanish
registry indicated a similar drug survival of the first and
second TNFi [48], confirming data from RCTs [49]. The
reason for stopping the first TNFi does not predict the re-
sponse to the second one, but the DAS28 score at the be-
ginning of the second TNFi treatment is a significant
predictor of EULAR response [45]. Various reports suggest
that the rate of response to the third drug is significantly
lower and that changing the target may be more useful:
for this reason, prescribing a third switch of TNFi does not
seem to be cost effective [50]. Moreover, increasing age and
comorbidities, in particular cardiovascular risk factors and
infections, are associated with reduced chances of receiving
a TNFi in clinical practice [51].
Safety
RCTs raised a number of safety concerns about an
increased risk of infections in patients treated with
TNFis. The greatest worry is related to tuberculosis (TB),
because the use of TNFis is accompanied by an increased
susceptibility to active TB or reactivation of a latent TB
infection [52]. In fact, TNF increases the phagocytic cap-
acity of macrophages, enhances intracellular killing of
mycobacterium and is also involved in the pathological
changes of latent TB infection, especially in maintaining
the formation and function of granulomas, which prevents
mycobacterium from disseminating into the blood [53, 54].
However, there have been reports indicating the occur-
rence of other serious infections during the use of TNFis,
including opportunistic infections. Large-population RA
registries have allowed us to study this aspect more exten-
sively than in RCTs and this may be due to substantial dif-
ferences in patient enrolment. The incidence of serious
infections (the ones that require i.v. antibiotic therapy and/
or hospitalization) appear to be quite similar among
registries [55, 56]. The most frequent are bacterial skin in-
fections and those involving the lower respiratory tract,
TABLE 2 Main European registries of patients with
inflammatory arthritis treated with bDMARDs
Registry Country Date
Number of
patients treated
with TNFis
LORHEN [35] Italy 1999 5200
GISEA [36] Italy 2005 12 500
BSRBR UK 2001 11 700
RABBIT Germany 2001 7600
BIOBADASER Spain 2000 5400
ARTIS Sweden 1999 7300
DANBIO Denmark 2000 3000
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however, a high rate of hospitalization due to pneumonia in
RA patients was also found regardless of TNFi treatment
[57, 58]. Risk factors for infections include the age at
which the biologic drug is started, the baseline ESR
and the concomitant use of a high dose of corticosteroids
[56, 58]. It has been suggested that monoclonal antibodies
carry a higher risk of TB [52], in particular infliximab, but this
may be due to the lack of TB screening when TNFis were
first introduced. Therapeutic approaches that include inten-
sive screening and surveillance seem to be advisable when
TNFis are used. Information about patients’ clinical history
should be carefully collected and all eligible patients should
be appropriately tested in order to assess the risk of TB
reactivation [59]. Prophylaxis with a standard anti-TB regi-
men has been shown to effectively prevent reactivation [60].
Among latent infections, HBV infection represents a major
issue in patients with RA on bDMARDs. HBV reactivation can
occur not only in HBsAg carriers, but also in HBsAg-negative
individuals presenting an occult HBV infection connected to
immunosuppression. Therefore, recommendations state
that all patients starting bDMARDs should be screened for
HBV infection. For HBsAg-positive patients, antiviral therapy
should be initiated before any bDMARD therapy, while for
patients with resolved HBV infection on a TNFi, simple moni-
toring without prophylactic treatment is recommended [61].
The increased use of TNFis in clinical practice raised con-
cerns about a possible association with cancer. Data from
registries showed that the overall incidence of cancer is
similar to that observed in the general population and in
patients on csDMARDs [6264] despite presenting a
higher risk of haematological malignancies [63]. However,
an increased risk of lymphomas has been attributed to RA
itself [65]. In patients on bDMARDs, non-melanoma skin
cancer may occur more frequently than in the general popu-
lation, but there was no increased risk when compared with
patients on csDMARDs, suggesting that monitoring skin
malignancies may be advisable in RA, irrespective of TNFi
treatment [66]. Only one study has shown that patients on
TNFi treatment may have an increased risk of melanoma
[67]. This finding should be taken into account in patients
with a high risk of melanoma due to other reasons.
Among other comorbidities in RA, particular interest has
been shown for cardiovascular diseases and correlated
risk factors, considering their strong association with the
level of disease activity [68, 69]. In a recent analysis from
the British Society for Rheumatology Biologics Register,
treatment with TNFis has been shown to be associated
with a reduced risk of myocardial infarction compared
with csDMARDs: this might be attributed to a direct
action of TNFi on atherosclerosis and to better overall dis-
ease control. TNFi may also reduce cardiovascular risk by
changing the lipid profile, insulin resistance and diabetes,
resulting in an overall beneficial effect [70].
Conclusions
TNFis were the first bDMARDs used in active RA in RCTs
and in clinical practice and have changed the concept of
RA from a universally debilitating disease to a goal of re-
mission of symptoms, disability and radiographic
progression. The use of TNFis has increased our know-
ledge of the disease itself, thus improving the way we deal
with it.
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